Baird Remains Bullish as Market Reacts to Cempra's (CEMP) 2nd Phase 3 Study of Solithromycin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cempra to Report Third Quarter 2015 Financial Results
October 19, 2015 8:02 AM EDTCHAPEL HILL, N.C., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report third quarter 2015 financial results before the open of U.S. financial markets on Thursday, October 22, 2015. Cempra management will host a webcast and conference call at 8:00 a.m. EDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-377-7553 for domestic callers... More
Cempra to Report Third Quarter 2015 Financial Results
October 19, 2015 8:01 AM EDTCHAPEL HILL, N.C., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report third quarter 2015 financial results before the open of U.S. financial markets on Thursday, October 22, 2015. Cempra management will host a webcast and conference call at 8:00 a.m. EDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-377-7553 for domestic callers... More
Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
October 16, 2015 7:00 AM EDTSolithromycin Met All FDA Primary Objectives of Non-Inferiority Compared to Moxifloxacin
Two Phase 3 Trials Required by the FDA and the EMA for CABP Regulatory Filings Now Complete
Rolling NDA Submission Expected to Begin 4Q 2015
Cempra to Host Webcast and Conference Call Today at 8:00 a.m. EDT
CHAPEL HILL, N.C., Oct. 16, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,... More
Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
October 16, 2015 7:00 AM EDTSolithromycin Met All FDA Primary Objectives of Non-Inferiority Compared to Moxifloxacin
Two Phase 3 Trials Required by the FDA and the EMA for CABP Regulatory Filings Now Complete
Rolling NDA Submission Expected to Begin 4Q 2015
Cempra to Host Webcast and Conference Call Today at 8:00 a.m. EDT
CHAPEL HILL, N.C., Oct. 16, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,... More
